SG11201911572YA - Adenoviral vectors - Google Patents

Adenoviral vectors

Info

Publication number
SG11201911572YA
SG11201911572YA SG11201911572YA SG11201911572YA SG11201911572YA SG 11201911572Y A SG11201911572Y A SG 11201911572YA SG 11201911572Y A SG11201911572Y A SG 11201911572YA SG 11201911572Y A SG11201911572Y A SG 11201911572YA SG 11201911572Y A SG11201911572Y A SG 11201911572YA
Authority
SG
Singapore
Prior art keywords
oxford
international
medawar
avenue
floor
Prior art date
Application number
SG11201911572YA
Inventor
Ryan Cawood
Weiheng Su
Original Assignee
Oxford Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1711971.0A external-priority patent/GB201711971D0/en
Priority claimed from GBGB1806375.0A external-priority patent/GB201806375D0/en
Application filed by Oxford Genetics Ltd filed Critical Oxford Genetics Ltd
Publication of SG11201911572YA publication Critical patent/SG11201911572YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB

Abstract

FigureW O 20 19/02099 2 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 31 January 2019 (31.01.2019) WIPO I PCT omit liononoi Imo lII ow (10) International Publication Number WO 2019/020992 Al (51) International Patent Classification: C12N 7/00 (2006.01) (21) International Application Number: PCT/GB2018/052083 (22) International Filing Date: 24 July 2018 (24.07.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1711971.0 25 July 2017 (25.07.2017) GB 1806375.0 19 April 2018 (19.04.2018) GB (71) Applicant: OXFORD GENETICS LIMITED [GB/GB]; First Floor, Medawar 1, Robert Robinson Avenue, The Ox- ford Science Park, Oxford Oxfordshire OX4 4GA (GB). (72) Inventors: CAWOOD, Ryan; c/o Oxford Genetics Ltd, First Floor, Medawar 1, Robert Robinson Avenue, The Ox- ford Science Park, Oxford Oxfordshire OX4 4GA (GB). SU, Weiheng; c/o Oxford Genetics Ltd, First Floor, Medawar 1, Robert Robinson Avenue, The Oxford Science Park, Oxford Oxfordshire OX4 4GA (GB). (74) Agent: DEHNS; St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — (54) Title: ADENOVIRAL VECTORS (57) : The present invention relates to an adenoviral vector com- prising a regulatable Major Late Promoter and an exogenous transgene. The invention also provides cells comprising such adenoviral vectors, and processes using such vectors. [Continued on next page] WO 2019/020992 Al MIDEDIMOMOIDIONOICIEHM01010110111011101011MOVOIMIE Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201911572YA 2017-07-25 2018-07-24 Adenoviral vectors SG11201911572YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1711971.0A GB201711971D0 (en) 2017-07-25 2017-07-25 Vectors
GBGB1806375.0A GB201806375D0 (en) 2018-04-19 2018-04-19 Vectors
PCT/GB2018/052083 WO2019020992A1 (en) 2017-07-25 2018-07-24 Adenoviral vectors

Publications (1)

Publication Number Publication Date
SG11201911572YA true SG11201911572YA (en) 2020-02-27

Family

ID=63077905

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911572YA SG11201911572YA (en) 2017-07-25 2018-07-24 Adenoviral vectors

Country Status (10)

Country Link
US (1) US20200239909A1 (en)
EP (1) EP3658668A1 (en)
JP (1) JP7105866B2 (en)
KR (1) KR102609021B1 (en)
CN (1) CN110892064A (en)
AU (1) AU2018307569B2 (en)
BR (1) BR112019027765A2 (en)
CA (1) CA3070654C (en)
SG (1) SG11201911572YA (en)
WO (1) WO2019020992A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4031670A4 (en) * 2019-09-16 2023-10-18 Excepgen Inc. Systems and methods for protein expression
CN115298316A (en) 2020-02-04 2022-11-04 牛津遗传学有限公司 Method for producing adeno-associated virus vector
GB202001484D0 (en) * 2020-02-04 2020-03-18 Oxford Genetics Ltd DNA amplification method
GB202013058D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Process for making a recombinant AAV library
GB202013060D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Cell line
GB202013057D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Method of making recombinant aavs
WO2022038367A1 (en) 2020-08-21 2022-02-24 Oxford Genetics Limited Process for making a recombinant aav library
CN112501207B (en) * 2020-12-07 2022-08-09 和元生物技术（上海）股份有限公司 Adenovirus packaging method capable of realizing controllable expression of exogenous gene
CN112501209B (en) * 2020-12-07 2024-02-13 和元生物技术（上海）股份有限公司 Method for packaging adeno-associated virus with controllable expression of exogenous gene
WO2022223954A1 (en) 2021-04-19 2022-10-27 Oxford Genetics Limited Dna amplification method using care elements
GB202105581D0 (en) 2021-04-19 2021-06-02 Oxford Genetics Ltd DNA amplification method
EP4112731A1 (en) * 2021-07-01 2023-01-04 Charité - Universitätsmedizin Berlin System for high-level raav production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3875990B2 (en) * 1993-10-25 2007-01-31 カンジ，インコーポレイテッド Recombinant adenoviral vectors and methods of use
NZ502175A (en) * 1998-04-15 2002-12-20 Univ New York State Res Found Selective regulation of adenovirus packaging with COUP-TF or lac repressor
US6383794B1 (en) * 1998-08-24 2002-05-07 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
HU226602B1 (en) 1998-10-15 2009-04-28 Canji Selectively replicating viral vectors, pharmaceutical preparations containing them and process for producing them
CN101035901A (en) * 2004-07-22 2007-09-12 细胞基因系统有限公司 Addition of transgenes into adenoviral vectors
KR20080052512A (en) * 2005-05-23 2008-06-11 박신, 인크. Rapid production of adenovirus-free recombinant adenovirus vectors
CN102533657B (en) * 2010-12-28 2015-04-22 中国疾病预防控制中心病毒病预防控制所 Human 41 type adenovirus (Ad41) packaging cell line and application thereof
GB202001484D0 (en) * 2020-02-04 2020-03-18 Oxford Genetics Ltd DNA amplification method

Also Published As

Publication number Publication date
KR102609021B1 (en) 2023-12-06
WO2019020992A1 (en) 2019-01-31
AU2018307569B2 (en) 2022-03-10
JP2020533956A (en) 2020-11-26
CA3070654A1 (en) 2019-01-31
JP7105866B2 (en) 2022-07-25
KR20200031141A (en) 2020-03-23
CA3070654C (en) 2021-07-27
EP3658668A1 (en) 2020-06-03
US20200239909A1 (en) 2020-07-30
AU2018307569A1 (en) 2020-02-20
CN110892064A (en) 2020-03-17
BR112019027765A2 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
SG11201911572YA (en) Adenoviral vectors
SG11201907653QA (en) Compositions and methods for enhanced gene expression
SG11201907857RA (en) Edible and biodegradable utensils
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201805186VA (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804541PA (en) Card handling devices and related assemblies and components
SG11201909203WA (en) Tissue selective transgene expression
SG11201811178UA (en) Adenoviral vector
SG11201808457PA (en) Icos ligand variant immunomodulatory proteins and uses thereof
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201908470UA (en) Enzymatic production of hexoses
SG11201811149TA (en) METABOLIC DRUG LOADING OF EVs
SG11201811637PA (en) Dynamic tug winch control
SG11201908042TA (en) Smartcard
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201906271QA (en) Potent and short promoter for expression of heterologous genes
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201811244SA (en) Dual overlapping adeno-associated viral vector system for expressing abc4a
SG11201804916PA (en) Three-dimensional polymer networks with channels situated therein
SG11201906973TA (en) Multiple transgene recombinant adenovirus